{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=52",
    "query": {
      "condition": "Ovary Disease",
      "page": 52
    },
    "page_size": 10
  },
  "pagination": {
    "page": 52,
    "page_size": 10,
    "total_count": 2270,
    "total_pages": 227,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=53&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=51&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T10:03:49.242Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00014690",
      "title": "ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "plevitrexed",
          "type": "DRUG"
        },
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "2001-03",
      "completion_date": "2004-02",
      "has_results": false,
      "last_update_posted_date": "2013-08-02",
      "last_synced_at": "2026-11-03T10:03:49.242Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00014690"
    },
    {
      "nct_id": "NCT07784582",
      "title": "Pre-pubertal Low Dose Transdermal Estradiol in Turner Syndrome",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Turner Syndrome",
        "Primary Ovarian Insufficiency"
      ],
      "interventions": [
        {
          "name": "Estradiol transdermal patch 0.025mg/24 hours- 1/8th fractionated patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's National Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "12 Years",
        "sex": "FEMALE",
        "summary": "8 Years to 12 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2026-09-01",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-11-03T10:03:49.242Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07784582"
    },
    {
      "nct_id": "NCT03440359",
      "title": "Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome"
      ],
      "interventions": [
        {
          "name": "Progesterone Vaginal Gel 8%",
          "type": "DRUG"
        },
        {
          "name": "Letrozole Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "pelvic ultrasound",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe",
          "type": "DRUG"
        },
        {
          "name": "Intrauterine insemination or timed intercourse",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "Eastern Virginia Medical School",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "20 Years to 40 Years · Female only"
      },
      "enrollment_count": 52,
      "start_date": "2012-07-06",
      "completion_date": "2017-12-30",
      "has_results": false,
      "last_update_posted_date": "2018-02-26",
      "last_synced_at": "2026-11-03T10:03:49.242Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03440359"
    },
    {
      "nct_id": "NCT00436865",
      "title": "Insulin and the Polycystic Ovary Syndrome--Weight Reduction Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Weight loss",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 79,
      "start_date": "2007-02",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2018-03-30",
      "last_synced_at": "2026-11-03T10:03:49.242Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00436865"
    },
    {
      "nct_id": "NCT06583395",
      "title": "Quest to Analyze One Thousand Humans Meditating",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Amyotrophic Lateral Sclerosis (ALS)",
        "Angina, Stable",
        "Anxiety",
        "Asthma",
        "Atrial Fibrillation",
        "Cancer Brain",
        "Cancer, Breast",
        "Cancer Colon",
        "Cancer, Lung",
        "Cancer, Ovarian",
        "Cancer Prostate",
        "Cancer Skin",
        "Throat Cancer",
        "Lymphoma",
        "Cancer, Thyroid",
        "Cancer, Other",
        "Cerebral Palsy",
        "Chronic Fatigue Syndrome",
        "Cluster Headache",
        "Chronic Obstructive Pulmonary Disease (COPD)",
        "Chronic Kidney Diseases",
        "Crohn Disease",
        "Deafness",
        "Depression",
        "Diabetes",
        "Eczema",
        "Epilepsy",
        "Fibroids",
        "Fibromyalgia",
        "Heart Failure",
        "Hypertension",
        "Hyperthyroidism",
        "Hypothyroidism",
        "Irritable Bowel Syndrome (IBS)",
        "Infertility",
        "Lyme Disease",
        "Macular Degeneration",
        "Migraine",
        "Multiple Allergies",
        "Multiple Sclerosis",
        "Osteoarthritis",
        "Osteoporosis",
        "Ovarian Cysts",
        "Parkinson Disease",
        "Phantom Limb Pain",
        "Psoriasis",
        "Post Traumatic Stress Disorder (PTSD)",
        "Rheumatoid Arthritis",
        "Sjogrens Disease",
        "Spinal Cord Injury",
        "Spinal Stenosis",
        "Stroke",
        "Tension Headache",
        "Tinnitus",
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Advanced multi-component meditation practice",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Tobias Moeller-Bertram",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 3000,
      "start_date": "2021-12-05",
      "completion_date": "2025-03-25",
      "has_results": false,
      "last_update_posted_date": "2024-11-01",
      "last_synced_at": "2026-11-03T10:03:49.242Z",
      "location_count": 1,
      "location_summary": "Palm Desert, California",
      "locations": [
        {
          "city": "Palm Desert",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06583395"
    },
    {
      "nct_id": "NCT00004065",
      "title": "Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bladder Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Gastric Cancer",
        "Head and Neck Cancer",
        "Kidney Cancer",
        "Leukemia",
        "Lung Cancer",
        "Melanoma (Skin)",
        "Ovarian Cancer",
        "Prostate Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "tanespimycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1999-07",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-11-03T10:03:49.242Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004065"
    },
    {
      "nct_id": "NCT03239145",
      "title": "Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Trebananib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2018-05-01",
      "completion_date": "2024-12-13",
      "has_results": true,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-03T10:03:49.242Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03239145"
    },
    {
      "nct_id": "NCT02333604",
      "title": "Cancer Experience Registry (CER) for Cancer Patients and Caregivers",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neoplasms",
        "Cancer",
        "Caregiver"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Cancer Support Community, Research and Training Institute, Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15000,
      "start_date": "2013-03",
      "completion_date": "2035-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-11-03T10:03:49.242Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02333604"
    },
    {
      "nct_id": "NCT00420381",
      "title": "Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Neoplasms",
        "Carcinoma"
      ],
      "interventions": [
        {
          "name": "enzastaurin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 28,
      "start_date": "2007-01",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-11-03T10:03:49.242Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00420381"
    },
    {
      "nct_id": "NCT01489371",
      "title": "EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Clear Cell Cystadenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Seromucinous Carcinoma",
        "Ovarian Serous Cystadenocarcinoma",
        "Ovarian Undifferentiated Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegylated Liposomal Doxorubicin Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2012-07-09",
      "completion_date": "2018-01-27",
      "has_results": false,
      "last_update_posted_date": "2019-03-12",
      "last_synced_at": "2026-11-03T10:03:49.242Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Orange, California • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01489371"
    }
  ]
}